AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Thyroid hormone receptor beta

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P10828

UPID:

THB_HUMAN

Alternative names:

Nuclear receptor subfamily 1 group A member 2; c-erbA-2; c-erbA-beta

Alternative UPACC:

P10828; B3KU79; P37243; Q13986; Q3KP35; Q6WGL2; Q9UD41

Background:

Thyroid hormone receptor beta, known as Nuclear receptor subfamily 1 group A member 2, c-erbA-2, or c-erbA-beta, is a pivotal nuclear hormone receptor. It acts as a repressor or activator of transcription with high affinity for thyroid hormones, including triiodothyronine and thyroxine.

Therapeutic significance:

This receptor is implicated in several thyroid hormone resistance syndromes, such as generalized autosomal dominant and recessive thyroid hormone resistance, and selective pituitary thyroid hormone resistance. These conditions highlight the receptor's crucial role in thyroid hormone regulation and its potential as a therapeutic target.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.